

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Status: Recruiting

Eligibility Criteria

Sex: Male

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of metastatic castration-resistant prostate cancer (mCRPC) - cancer is adenocarcinoma type - prior orchiectomy and/or ongoing androgen-deprivation therapy (ADT) - unable to do physically strenuous activity but walking and able to carry out work of a light or sedentary nature, e.g., light house work, office work - see link to clinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- history of central nervous system (CNS) metastases - disease progression on or intolerance to abiraterone - see link to clinicaltrials.gov for complete exclusion criteria

Conditions & Interventions

Interventions:

Drug: Abiraterone acetate, Drug: Cabazitaxel, Drug: Docetaxel, Drug: Xaluritamig

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), mCRPC, Metastatic Castration-resistant Prostate Cancer

More Information

Description: This research study is being done to learn more about how safe and effective the investigational drug xaluritamig is when given in combination with abiraterone acetate compared to standard care (study doctor's choice of abiraterone acetate, docetaxel, or cabazitaxel) in people with prostate cancer that has spread to other parts of the body but has not yet been treated with chemotherapy (also known as chemotherapy naïve Metastatic Castration-Resistant Prostate Cancer [mCRPC]).

Study Contact: Nicholas Zorko - zorko004@umn.edu

Principal Investigator: Nicholas Zorko

Phase: PHASE3

IRB Number: STUDY00026650

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.